An optimized bicistronic chimeric antigen receptor against GPC2 or CD276 overcomes heterogeneous expression in neuroblastoma

Chimeric antigen receptor (CAR) T cell therapies targeting single antigens have performed poorly in clinical trials for solid tumors due to heterogenous expression of tumor-associated antigens (TAAs), limited T cell persistence, and T cell exhaustion. Here, we aimed to identify optimal CARs against...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Journal of clinical investigation 2022-08, Vol.132 (16), p.1-17
Hauptverfasser:	Tian, Meijie, Cheuk, Adam T, Wei, Jun S, Abdelmaksoud, Abdalla, Chou, Hsien-Chao, Milewski, David, Kelly, Michael C, Song, Young K, Dower, Christopher M, Li, Nan, Qin, Haiying, Kim, Yong Yean, Wu, Jerry T, Wen, Xinyu, Benzaoui, Mehdi, Masih, Katherine E, Wu, Xiaolin, Zhang, Zhongmei, Badr, Sherif, Taylor, Naomi, St Croix, Brad, Ho, Mitchell, Khan, Javed
Format:	Artikel
Sprache:	eng
Schlagworte:	Antigen (tumor-associated) Antigens Biomedical research Cell adhesion & migration Children Chimeric antigen receptors Clinical trials Cytotoxicity Epitopes Heparan sulfate proteoglycans Immunotherapy Kinases Lymphocytes Lymphocytes T Lymphoma Medical prognosis Metastasis Neuroblastoma Pediatrics Protein expression Proteins Solid tumors Transcriptomes Tumor cells Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!